In a Game Changer Session at EAU25, Prof. Kellokumpu-Lehtinen Pirkko-Liisa presented the 10-year follow-up from the Scandinavian Prostate Cancer Study Group-13 trial (SPCG-13), exploring adjuvant docetaxel versus surveillance following curative radiotherapy in patients with intermediate- or high-risk prostate cancer.
Key Findings:
At 10 years, survival was long in both groups, with no statistically significant difference observed.
High-Gleason patients appeared to benefit more from docetaxel.
However, better predictive markers are needed to guide adjuvant treatment decisions.
Despite prior efficacy in metastatic hormone-naïve prostate cancer (STAMPEDE, CHAARTED), docetaxel showed limited effect in the earlier curative setting.
While the primary hypothesis was not confirmed, this trial highlights the complexity of selecting patients for adjuvant chemotherapy in localized prostate cancer and the need for biomarker-driven personalization moving forward.
A sincere thank you to Prof. Kellokumpu-Lehtinen Pirkko-Liisa for this important presentation and to all investigators and patients who contributed to the SPCG-13 trial.
